Eloralintide Guide
Eli Lilly
Complete guide to Eloralintide (LY3841136) — Eli Lilly
What Is Eloralintide?
Eloralintide (development code LY3841136) is Eli Lilly's investigational selective amylin receptor agonist. Unlike GLP-1 drugs such as Semaglutide (Wegovy/Ozempic) or dual agonists like Tirzepatide (Mounjaro/Zepbound), Eloralintide works through an entirely different hormonal pathway.
Amylin is a peptide hormone naturally co-secreted with insulin by the pancreatic beta-cells in response to food intake. It plays a central role in controlling how fast your stomach empties, suppressing post-meal glucagon release, and signaling fullness to the brain. By selectively targeting the amylin 1 receptor (AMY1R), Eloralintide amplifies these natural satiety signals to reduce calorie intake and promote significant weight loss.
This makes Eloralintide a distinct and complementary tool in the metabolic medicine landscape, potentially working alongside GLP-1 therapies rather than simply competing with them. Eli Lilly is already studying Eloralintide in combination with tirzepatide. Track your current protocol in Shotlee while this science evolves.
The Amylin Mechanism
Satiety Signaling
Activates amylin 1 receptors (AMY1R). Signals fullness to the brain earlier. Reduces calorie intake naturally. Track appetite changes in Shotlee
Gastric & Glucagon Control
Slows gastric emptying rate. Inhibits post-meal glucagon secretion. Helps stabilize blood sugar levels. Log GI symptoms in Shotlee
Fat-Targeted Loss
60-70% of weight loss is fat mass. Preserves lean muscle tissue. Improves body composition ratio. Monitor body composition in Shotlee
Why This Matters
Amylin-based weight loss is mechanistically distinct from GLP-1 therapies. This opens the door to combination approaches — Eli Lilly is already testing Eloralintide together with tirzepatide. Tracking
Phase 2 Clinical Results (48 Weeks)
Top Weight Loss
-20%
Deep Responders
57%
Fat Mass
60-70%
Side Effects
Most Common
Nausea (32.7% vs 13.5% placebo). Fatigue. Mild GI symptoms. More prevalent at higher doses. Log all side effects in Shotlee
Tolerability
Generally well tolerated overall. Slower dose escalation reduces side effects. Low-dose arms (1-3 mg) similar to placebo. No major safety signals identified. Track symptom trends over time in Shotlee
Eloralintide vs Current Options
All listed medications can be tracked in the free Shotlee app. Build your baseline data now and compare how different drug classes — including amylin agonists — perform for your body over time.
Vital Protocol FAQs
Is Eloralintide a GLP-1 drug?
No. Eloralintide is a selective amylin receptor agonist, which is a fundamentally different drug class from GLP-1 medications. It works through the amylin hormone pathway rather than GLP-1 signaling.
Can I get Eloralintide now?
No, Eloralintide is not yet approved or available outside of clinical trials. Phase 3 trials are expected to begin by end of 2025. In the meantime, use Shotlee to track your current FDA-approved proto
How does it compare to Semaglutide?
They target completely different receptors. Semaglutide is a GLP-1 agonist; Eloralintide is an amylin agonist. In Phase 2, Eloralintide at 9 mg showed about 20% weight loss, which is competitive with
Why should I start tracking now?
Having clean baseline data is invaluable. When amylin agonists like Eloralintide become available, you will be able to see exactly how your body responds compared to your previous GLP-1 protocol. Shot
Guide FAQs
Complete guide to Eloralintide (LY3841136) — Eli Lilly
Yes. Shotlee supports tracking Eloralintide doses, side effects, and health metrics. It is free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Eloralintide research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Eloralintide, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Eloralintide protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Eloralintide data in Shotlee to identify which combinations drive your best results.
References
Track Your Eloralintide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free